Adamas Pharmaceuticals Announces Closing of Its Initial Public Offering
PR Newswire - Tue Apr 15, 3:00PM CDT
Adamas Pharmaceuticals, Inc. (Adamas) (Nasdaq:ADMS), a specialty pharmaceutical company, today announced the closing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of $16.00 per share. The shares began trading on The NASDAQ Global Market under the ticker symbol "ADMS" on April 10, 2014. Adamas estimates net proceeds from the offering to be approximately $41.5 million after deducting underwriting discounts and commissions and estimated offering expenses.
Biotech IPOs Adamas, Cerulean Slump In Trading Debut
at Investor's Business Daily - Thu Apr 10, 3:02PM CDT
Adamas Pharmaceuticals (ADMS) and Cerulean Pharma (CERU) launched IPOs Thursday, two of four biotechs expected to debut this week. Adamas priced at 16, the low end of its range. In late afternoon trading, the stock was near 15.30 on the stock market...
Adamas Pharma wavers after IPO raises $48 million
AP - Thu Apr 10, 10:40AM CDT
NEW YORK (AP) — Shares of Adamas Pharmaceuticals wavered Thursday after the drug developer's initial public offering raised $48 million.
Steve Bederman Thought-Technology Leader is Hosting the 2nd in a Webinar Series, "Modernize Your Marketing with the Most Advanced Messaging Solutions in the Marketplace"
PRWeb - Thu Apr 25, 1:07AM CDT
Communication and technology are forever evolving and changing. In the United States alone, approximately 91% of the population has their mobile device within reach 24/7. Additionally, the average user looks at their phone 150 times a day.